Adragos Pharma

Executive Summary

Adragos Pharma is a global Contract Development and Manufacturing Organization (CDMO) headquartered in Munich, Germany, founded in 2018. The company specializes in small molecules and biologicals, offering comprehensive development and manufacturing services for drug products across various dosage forms. With a network of state-of-the-art facilities in Europe and Japan, Adragos provides end-to-end solutions from clinical to commercial manufacturing, enabling clients to streamline their supply chains and accelerate time-to-market. The company's integrated approach and focus on quality position it as a reliable partner for pharmaceutical companies seeking flexible and scalable CDMO services. Despite being categorized as pre-clinical, Adragos operates as an active CDMO with a growing footprint. The global CDMO market is expanding due to increasing outsourcing trends and demand for specialized manufacturing capabilities. Adragos is well-positioned to capitalize on this growth, leveraging its expertise in both small molecules and biologicals. Key opportunities include expanding its facility network, forming strategic alliances with biotech and pharma firms, and winning contracts for late-stage or commercial manufacturing projects. The company's private status and lack of disclosed financials suggest a focus on operational growth over near-term exits.

Upcoming Catalysts (preview)

• Q2 2027Expansion of manufacturing capacity in Europe or Japan70% success
• Q4 2026Strategic partnership with a top-20 pharmaceutical company40% success
• TBDClient drug using Adragos manufacturing achieves FDA approval30% success